

Definitions for severely or moderately immunocompromised patients	
Severely immune compromised patients:	<ol style="list-style-type: none"> <li>1. Solid organ transplant recipient</li> <li>2. Being actively treated for hematological malignancy</li> <li>3. Received bone marrow or stem cell transplant</li> <li>4. Taken anti-CD20 agents or B cell depleting agents</li> <li>5. Severe primary immune deficiencies</li> <li>6. Taken anti CD20 agents or B cells depleting agents for non hematological reason</li> </ol>
Moderately immune compromised patients:	<ol style="list-style-type: none"> <li>1. Received treatment for cancer including solid tumors:               <ol style="list-style-type: none"> <li>a. Have received or are receiving systemic therapy (including chemotherapy, molecular therapy, immunotherapy, targeted therapies including CAR-T, monoclonal antibodies other than the hematological malignancies noted above (severely immune compromised patients), EXCEPT those receiving adjunctive hormonal therapy ONLY</li> <li>b. Have received or are receiving radiation therapy for cancer</li> </ol> </li> <li>2. Taken significantly immune suppressing medication who are not already captured above (severely immune compromised patients):               <ol style="list-style-type: none"> <li>a. Biologics: abatacept, adalimumab, anakinra, benralizumab, brodalumab, canakinumab, certolizumab, dupilumab, etanercept, golimumab, guselkumab, infliximab, interferon products (alpha, beta, and pegylated forms), ixekizumab, mepolizumab, natalizumab, omalizumab, reslizumab, risankizumab, sarilumab, secukinumab, tildrakizumab, tocilizumab, ustekinumab, or vedolizumab;</li> <li>b. Oral immune-suppressing drugs: azathioprine, baricitinib, cyclophosphamide, cyclosporine, leflunomide, dimethyl fumerate, everolimus, fingolimod, mycophenolate, siponimod, sirolimus, tacrolimus, tofacitinib, upadacitinib, methotrexate, or teriflunomide;</li> <li>c. Oral steroids on an ongoing basis: dexamethasone, hydrocortisone, methylprednisolone, or prednisone; vi. Immune-suppressing infusions/injections: cladribine, cyclophosphamide, glatiramer, methotrexate</li> </ol> </li> <li>3. Advanced untreated HIV infection or those with acquired immunodeficiency syndrome (AIDS) defined as AIDS defining illness or CD4 count <math>\leq 200/\text{mm}^3</math> or CD4 fraction <math>\leq 15\%</math></li> <li>4. Moderate primary immunodeficiencies: Have a moderate to severe primary immunodeficiency which has been diagnosed by an adult or pediatric immunologist and requires ongoing immunoglobulin replacement therapy (IVIg or SCIG) or the primary immunodeficiency has a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)</li> <li>5. Glomerulonephritis and receiving steroid treatment</li> </ol>

